NCT04618211 - Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 3, 2021

Primary Completion Date

September 23, 2022

Study Completion Date

March 1, 2023

Conditions

Hereditary AngioedemaHereditary Angioedema Type IHereditary Angioedema Type IIHereditary Angioedema Types I and IIHereditary Angioedema AttackHereditary Angioedema With C1 Esterase Inhibitor DeficiencyHereditary Angioedema - Type 1Hereditary Angioedema - Type 2C1 Esterase Inhibitor DeficiencyC1 Inhibitor Deficiency

Interventions

DRUG

Deucrictibant

deucrictibant soft capsules for oral use

DRUG

Placebo

Matching placebo capsules for oral use

Trial Locations (36)

17033

Study site, Hershey

20815

Study site, Chevy Chase

35209

Study site, Birmingham

63141

Study site, St Louis

85253

Study site, Paradise Valley

90404

Study site, Santa Monica

92122

Study site, San Diego

94598

Study site, Walnut Creek

Unknown

Study site, Sofia

Study site, Edmonton

Study site, Ottawa

Study site, Toronto

Study site, Montreal

Study site, Québec

Study site, Brno

Study site, Hradec Králové

Study site, Grenoble

Study site, Montpellier

Study site, Paris

Study site, Berlin

Study site, Dresden

Study site, Frankfurt

Study site, Mainz

Study site, Ulm

Study site, Budapest

Study site, Ashkelon

Study site, Haifa

Study site, Tel Aviv

Study site, Monserrato

Study site, Naples

Study site, Amsterdam

Study site, Krakow

Study site, Barcelona

Study site, Madrid

Study site, Brighton

Study site, London

All Listed Sponsors

lead

Pharvaris Netherlands B.V.

INDUSTRY